Ovid Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 1.45 million compared to USD 208.38 million a year ago. Net loss was USD 16.11 million compared to net income of USD 176.01 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to basic earnings per share from continuing operations of USD 2.55 a year ago. Diluted loss per share from continuing operations was USD 0.23 compared to diluted earnings per share from continuing operations of USD 2.53 a year ago.